Journal of Neurology

, Volume 252, Issue 8, pp 904–907

Botulinum toxin type B de novo therapy of cervical dystonia

Frequency of antibody induced therapy failure
ORIGINAL COMMUNICATION

DOI: 10.1007/s00415-005-0774-3

Cite this article as:
Dressler, D. & Bigalke, H. J Neurol (2005) 252: 904. doi:10.1007/s00415-005-0774-3
  • 69 Downloads

Abstract

Botulinum toxin induced therapy failure type B antibody (BT–B, BT–B–AB) has so far only been reported after previous formation of antibodies against botulinum toxin type A (BT–A, BTA– AB).We wanted to explore the risk of BT-B-AB-induced therapy failure in patients who were exposed to botulinum toxin for the first time.

For this purpose we followed nine patients with cervical dystonia receiving BT-B (NeuroBloc®/Myo- Bloc™, Elan Pharmaceuticals) in a dose of 11435 ± 2977MU during 4.9 ± 3.0 injection series. All patients showed a satisfactory initial therapeutic response as documented by a Toronto Western Spasmodic Torticollis Rating Scale score reduction from 17.7 ± 9.4 to 5.3 ± 4.8 and an overall subjective improvement of 56.1 ± 28.3%. Seven patients experienced systemic anticholinergic side effects. Five patients had stable therapeutic responses over subsequent injection series. Four patients experienced complete therapy failure with BT–B–AB titres in excess of 10mU/ml on the mouse diaphragm assay. Doubling the last effective BT–B dose produced neither therapeutic effects nor side effects. Subsequent applications of botulinum toxin type A produced a continued therapeutic response in one patient and complete therapy failure in the other.

Despite the small sample size a frequency of 44 % indicates a high risk for BT–B–AB-induced complete therapy failure. The high amount of neurotoxin administered when NeuroBloc®/MyoBloc™ is used might be a contributory factor. Further prospective comparative studies are necessary to monitor the frequency and time course of BT–B–AB formation.

Key words

botulinum toxin type B therapy failure de novo therapy botulinum toxin type A electromyography antibody formation 

Copyright information

© Steinkopff-Verlag 2005

Authors and Affiliations

  1. 1.Dept. of Neurology Rostock UniversityRostockGermany
  2. 2.Institute of Toxicology Medizinische HochschuleHannoverGermany

Personalised recommendations